US 12,343,319 B2
Compositions and methods for treatment of diseases and disorders
Carrie Bowen, Encinitas, CA (US); Glenn F. Short, Encinitas, CA (US); and Thomas Cameron Robertson, Encinitas, CA (US)
Assigned to Atai Therapeutics, Inc., New York, NY (US)
Filed by Atai Therapeutics Inc., New York, NY (US)
Filed on May 1, 2024, as Appl. No. 18/652,721.
Claims priority of provisional application 63/567,737, filed on Mar. 20, 2024.
Claims priority of provisional application 63/545,825, filed on Oct. 26, 2023.
Claims priority of provisional application 63/463,202, filed on May 1, 2023.
Prior Publication US 2024/0366531 A1, Nov. 7, 2024
Int. Cl. A61K 31/137 (2006.01); A61P 25/20 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/137 (2013.01) [A61P 25/20 (2018.01); A61P 25/24 (2018.01)] 13 Claims
 
1. A method of treating a sleep dysfunction or a sleep disorder in a subject comprising administering to the subject a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; wherein
R1 is independently at each position hydrogen, C1-C6 alkyl, or C1-C6haloalkyl;
R2, R3 and R7 are independently hydrogen, heterocycle, C1-C6 alkyl, C1-C6 haloalkyl, halogen, cyano, OR1, S(O)(=NH)R1, S(O)2R1, S(O)R1 or SR1, wherein at least one of R2 and R3 is hydrogen;
R4, R5 and R6 are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, halogen, cyano, OR1, SR1, (C═O)(R14), O(C═O)(R14), NO2, or NH(C═O)(R14), wherein R14 is C1-C6 alkyl, OH, or OC1-C6 alkyl;
R8 and R9 are independently hydrogen, C1-C6 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C10 cycloalkyl, CH2OH, or CH2O—C1-C4 alkyl;
R10 and R11 are independently hydrogen, halogen, C1-C6 alkyl, OH, C1-C4 alkyl, C3-C6 cycloalkyl, or CH2O—C1-C4 alkyl;
R12 is hydrogen, CH2OH, CH2O—C1-C9 alkyl, C3-C10 cycloalkyl, CH2OH, or CH2O—C1-C4 alkyl; and
R13 is hydrogen, C1-C9 alkyl, C3-C10 cycloalkyl, CH2OH, or CH2O—C1-C4 alkyl,
thereby treating the sleep dysfunction or the sleep disorder in the subject.